{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:47:19Z","timestamp":1787021239887,"version":"build-2736575974"},"reference-count":48,"publisher":"The Endocrine Society","issue":"5","license":[{"start":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007775","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007775","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003358","name":"Gedeon-Richter","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003358","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"Astra-Zeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012317","name":"Astellas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012317","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Eli Lilly"},{"name":"PharmaPrim"},{"name":"EffRx"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The purpose of this observational study was to investigate the effectiveness and safety of romosozumab (ROMO) and teriparatide (TPTD) in a clinical setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 315 postmenopausal women were included based on the reimbursement criteria for ROMO and TPTD at the Department of Endocrinology at Aarhus University Hospital. Criteria for ROMO were bone mineral density (BMD) T-score &amp;lt; \u22122.5 (femoral neck [FN], total hip [TH], or lumbar spine [LS]) + a fragility fracture (hip, spine, pelvis, distal forearm, or proximal humerus) within 3 years. Criteria for TPTD: within 3 years, \u2265 2 vertebral fractures or 1 vertebral fracture + BMD T-score (FN, TH, or LS) &amp;lt; \u22123. Data were collected from medical records. The primary end point was percentage change from baseline in BMD (FN, TH, and LS) at month 12. BMD was measured by dual-energy x-ray absorptiometry (DXA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At month 12, ROMO led to significantly (P &amp;lt; .001) larger increases than TPTD in BMD (FN: 4.8% vs 0.2%, TH: 5.7% vs 0.3%, and LS: 13.7% vs 9.3%). Discontinuation rate was lower with ROMO than with TPTD. Lower incidence of cardiovascular adverse events was observed with ROMO compared to TPTD. Treatment-na\u00efve patients had nonsignificantly higher BMD increases compared to previously treated patients with both ROMO and TPTD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Treatment with ROMO yields larger increases in BMD than TPTD after 12 months and a higher rate of completion. ROMO was associated with a higher adherence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgae484","type":"journal-article","created":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T01:30:17Z","timestamp":1720834217000},"page":"e1640-e1652","source":"Crossref","is-referenced-by-count":20,"title":["The Effectiveness and Safety of Romosozumab and Teriparatide in Postmenopausal Women With Osteoporosis"],"prefix":"10.1210","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0339-0788","authenticated-orcid":false,"given":"Martin C","family":"Hartz","sequence":"first","affiliation":[{"name":"Section for Bone Diseases, Department of Endocrinology, Aarhus University Hospital , 8200 Aarhus ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5535-2078","authenticated-orcid":false,"given":"Fabian B","family":"Johannessen","sequence":"additional","affiliation":[{"name":"Section for Bone Diseases, Department of Endocrinology, Aarhus University Hospital , 8200 Aarhus ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8581-3523","authenticated-orcid":false,"given":"Torben","family":"Harsl\u00f8f","sequence":"additional","affiliation":[{"name":"Section for Bone Diseases, Department of Endocrinology, Aarhus University Hospital , 8200 Aarhus ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8712-7199","authenticated-orcid":false,"given":"Bente L","family":"Langdahl","sequence":"additional","affiliation":[{"name":"Section for Bone Diseases, Department of Endocrinology, Aarhus University Hospital , 8200 Aarhus ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2024,7,16]]},"reference":[{"key":"2025042208273077300_dgae484-B1","volume-title":"International Osteoporosis Foundation\u2014Compendium of Osteoporosis\u20142nd ed","author":"Cooper","year":"2019"},{"key":"2025042208273077300_dgae484-B2","volume-title":"Osteoporose: en afd\u00e6kning af den samlede indsats mod osteoporose","author":"Danmark and Sundhedsstyrelsen","year":"2018"},{"issue":"1","key":"2025042208273077300_dgae484-B3","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1186\/s13018-021-02772-0","article-title":"The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis","volume":"16","author":"Salari","year":"2021","journal-title":"J Orthop Surg"},{"key":"2025042208273077300_dgae484-B4","volume-title":"Knoglesk\u00f8rhed","author":"Osteoporoseforeningen","year":"2023"},{"key":"2025042208273077300_dgae484-B5","volume-title":"Notat til Folketingets Europaudvalg samt grundnotat om forslag til kommissionsbeslutning om udstedelse af markedsf\u00f8ringstilladelsefor l\u00e6gemidlet \u201cForsteo \u2013 Teriparatide","author":"Folketingets Sundhedsudvalg","year":"2003"},{"issue":"2","key":"2025042208273077300_dgae484-B6","first-page":"1","article-title":"Behandling af prim\u00e6r osteoporose i almen praksis","volume":"2019","author":"Laut","year":"2019","journal-title":"Ration Farmakoter"},{"key":"2025042208273077300_dgae484-B7","volume-title":"Medicinr\u00e5dets anbefaling vedr\u00f8rende romosozumab til behandling af sv\u00e6r osteoporose hos postmenopausale kvinder med h\u00f8j risiko for fraktur","author":"Medicinr\u00e5det","year":"2020"},{"key":"2025042208273077300_dgae484-B8","volume-title":"Teriparatide","author":"Vall","year":"2022"},{"issue":"15","key":"2025042208273077300_dgae484-B9","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"issue":"16","key":"2025042208273077300_dgae484-B10","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"2025042208273077300_dgae484-B11","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"issue":"10","key":"2025042208273077300_dgae484-B12","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1007\/s00198-020-05463-4","article-title":"Efficacy of teriparatide compared with risedronate on FRAX\u00ae-defined major osteoporotic fractures: results of the VERO clinical trial","volume":"31","author":"Body","year":"2020","journal-title":"Osteoporos Int"},{"issue":"19","key":"2025042208273077300_dgae484-B13","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"issue":"9","key":"2025042208273077300_dgae484-B14","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/jbmr.3176","article-title":"Greater gains in spine and hip strength for romosozumab compared with teriparatide in postmenopausal women with low bone mass: bONE-STRENGTHENING EFFECTS OF ROMOSOZUMAB","volume":"32","author":"Keaveny","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2025042208273077300_dgae484-B15","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/jbmr.2932","article-title":"Effects of romosozumab compared with teriparatide on bone density and mass at the spine and hip in postmenopausal women with low bone mass: QCT ASSESSED DENSITY\/MASS WITH ROMOSOZUMAB\/TERIPARATIDE","volume":"32","author":"Genant","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"10102","key":"2025042208273077300_dgae484-B16","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet"},{"key":"2025042208273077300_dgae484-B17","volume-title":"Evenity (romosozumab)","author":"European Medicines Agency","year":"2019"},{"key":"2025042208273077300_dgae484-B18","doi-asserted-by":"crossref","first-page":"115121","DOI":"10.1016\/j.bone.2019.115121","article-title":"Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: systematic review and meta- analysis","volume":"130","author":"Lv","year":"2020","journal-title":"Bone"},{"issue":"1","key":"2025042208273077300_dgae484-B19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11914-020-00652-w","article-title":"Romosozumab: a review of efficacy, safety, and cardiovascular risk","volume":"19","author":"Fixen","year":"2021","journal-title":"Curr Osteoporos Rep"},{"issue":"7","key":"2025042208273077300_dgae484-B20","doi-asserted-by":"crossref","first-page":"e187","DOI":"10.1161\/ATVBAHA.122.317635","article-title":"Role of sclerostin in cardiovascular disease","volume":"42","author":"Golledge","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9","key":"2025042208273077300_dgae484-B21","doi-asserted-by":"crossref","first-page":"e10665","DOI":"10.1002\/jbm4.10665","article-title":"Teriparatide and osteosarcoma risk: history, science, elimination of boxed warning, and other label updates","volume":"6","author":"Krege","year":"2022","journal-title":"JBMR Plus"},{"issue":"1","key":"2025042208273077300_dgae484-B22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jbmr.173","article-title":"Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody","volume":"26","author":"Padhi","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2025042208273077300_dgae484-B23","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1007\/s00198-021-05925-3","article-title":"Early clinical effects, safety, and predictors of the effects of romosozumab treatment in osteoporosis patients: one-year study","volume":"32","author":"Tominaga","year":"2021","journal-title":"Osteoporos Int"},{"issue":"1","key":"2025042208273077300_dgae484-B24","doi-asserted-by":"crossref","first-page":"11801","DOI":"10.1038\/s41598-021-91248-6","article-title":"Denosumab versus romosozumab for postmenopausal osteoporosis treatment","volume":"11","author":"Kobayakawa","year":"2021","journal-title":"Sci Rep"},{"key":"2025042208273077300_dgae484-B25","doi-asserted-by":"crossref","first-page":"115574","DOI":"10.1016\/j.bone.2020.115574","article-title":"Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis","volume":"140","author":"Ebina","year":"2020","journal-title":"Bone"},{"issue":"7","key":"2025042208273077300_dgae484-B26","doi-asserted-by":"crossref","first-page":"e10637","DOI":"10.1002\/jbm4.10637","article-title":"The real-world effect of 12 months of romosozumab treatment on patients with osteoporosis with a high risk of fracture and factors predicting the rate of bone mass increase: a multicenter retrospective study","volume":"6","author":"Inose","year":"2022","journal-title":"JBMR Plus"},{"issue":"6","key":"2025042208273077300_dgae484-B27","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s00198-021-06261-2","article-title":"Effect of the duration of previous osteoporosis treatment on the effect of romosozumab treatment","volume":"33","author":"Tominaga","year":"2022","journal-title":"Osteoporos Int"},{"key":"2025042208273077300_dgae484-B28","doi-asserted-by":"crossref","first-page":"116480","DOI":"10.1016\/j.bone.2022.116480","article-title":"Verification of efficacy and safety of ibandronate or denosumab for postmenopausal osteoporosis after 12-month treatment with romosozumab as sequential therapy: the prospective VICTOR study","volume":"162","author":"Kobayakawa","year":"2022","journal-title":"Bone"},{"key":"2025042208273077300_dgae484-B29","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.clnesp.2022.02.002","article-title":"Effects of romosozumab with and without active vitamin D analog supplementation for postmenopausal osteoporosis","volume":"48","author":"Kobayakawa","year":"2022","journal-title":"Clin Nutr ESPEN"},{"issue":"3","key":"2025042208273077300_dgae484-B30","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/jbmr.238","article-title":"Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis","volume":"26","author":"Cosman","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2025042208273077300_dgae484-B31","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1002\/jbmr.3735","article-title":"Bone-forming and antiresorptive effects of romosozumab in postmenopausal women with osteoporosis: bone histomorphometry and microcomputed tomography analysis after 2 and 12 months of treatment","volume":"34","author":"Chavassieux","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2025042208273077300_dgae484-B32","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40266-019-00675-8","article-title":"Current Status of bone-forming therapies for the management of osteoporosis","volume":"36","author":"S\u00f8lling","year":"2019","journal-title":"Drugs Aging"},{"issue":"3","key":"2025042208273077300_dgae484-B33","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00198-016-3888-9","article-title":"Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States","volume":"28","author":"Burge","year":"2017","journal-title":"Osteoporos Int"},{"issue":"3","key":"2025042208273077300_dgae484-B34","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1359\/jbmr.2003.18.3.539","article-title":"Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis","volume":"18","author":"Zanchetta","year":"2003","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2025042208273077300_dgae484-B35","doi-asserted-by":"crossref","first-page":"e10736","DOI":"10.1002\/jbm4.10736","article-title":"Fracture risk in men and women with vertebral fractures identified opportunistically on routine computed tomography scans and not treated for osteoporosis: an observational cohort study","volume":"7","author":"Skj\u00f8dt","year":"2023","journal-title":"JBMR Plus"},{"issue":"6","key":"2025042208273077300_dgae484-B36","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s00198-021-06174-0","article-title":"Romosozumab and antiresorptive treatment: the importance of treatment sequence","volume":"33","author":"Cosman","year":"2022","journal-title":"Osteoporos Int"},{"issue":"10","key":"2025042208273077300_dgae484-B37","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1359\/jbmr.080506","article-title":"Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment","volume":"23","author":"Obermayer-Pietsch","year":"2008","journal-title":"J Bone Miner Res"},{"key":"2025042208273077300_dgae484-B38","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.bone.2016.10.008","article-title":"Sclerostin's role in bone's adaptive response to mechanical loading","volume":"96","author":"Galea","year":"2017","journal-title":"Bone"},{"issue":"1","key":"2025042208273077300_dgae484-B39","doi-asserted-by":"crossref","first-page":"C53","DOI":"10.1152\/ajpcell.00175.2017","article-title":"Recombinant sclerostin antagonizes effects of ex vivo mechanical loading in trabecular bone and increases osteocyte lacunar size","volume":"314","author":"Kogawa","year":"2018","journal-title":"Am J Physiol-Cell Physiol"},{"issue":"5","key":"2025042208273077300_dgae484-B40","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3109\/17453674.2011.625539","article-title":"Anti-sclerostin antibody and mechanical loading appear to influence metaphyseal bone independently in rats","volume":"82","author":"Agholme","year":"2011","journal-title":"Acta Orthop"},{"issue":"11","key":"2025042208273077300_dgae484-B41","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1002\/jbmr.2278","article-title":"Mechanical load increases in bone formation via a sclerostin-independent pathway: bONE FORMATION VIA A SCLEROSTIN-INDEPENDENT PATHWAY","volume":"29","author":"Morse","year":"2014","journal-title":"J Bone Miner Res"},{"key":"2025042208273077300_dgae484-B42","doi-asserted-by":"crossref","first-page":"116087","DOI":"10.1016\/j.bone.2021.116087","article-title":"The Wnt pathway: an important control mechanism in bone's response to mechanical loading","volume":"153","author":"Choi","year":"2021","journal-title":"Bone"},{"issue":"2","key":"2025042208273077300_dgae484-B43","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/jbmr.4467","article-title":"Circulating sclerostin levels are positively related to coronary artery disease severity and related risk factors","volume":"37","author":"Frysz","year":"2020","journal-title":"J Bone Miner Res"},{"key":"2025042208273077300_dgae484-B44","first-page":"174550572211255","article-title":"Romosozumab for the treatment of osteoporosis in women: efficacy, safety, and cardiovascular risk","volume":"18","author":"Lim","year":"2022","journal-title":"Womens Health"},{"key":"2025042208273077300_dgae484-B45","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.atherosclerosis.2016.06.039","article-title":"Bisphosphonates for cardiovascular risk reduction: a systematic review and meta-analysis","volume":"252","author":"Kranenburg","year":"2016","journal-title":"Atherosclerosis"},{"issue":"6","key":"2025042208273077300_dgae484-B46","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s00198-021-06271-0","article-title":"Romosozumab and cardiovascular safety\u2014should we learn lessons from pioglitazone?","volume":"33","author":"Jacob","year":"2022","journal-title":"Osteoporos Int"},{"issue":"6","key":"2025042208273077300_dgae484-B47","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s00198-020-05379-z","article-title":"Explanations for the difference in rates of cardiovascular events in a trial of alendronate and romosozumab","volume":"31","author":"Cummings","year":"2020","journal-title":"Osteoporos Int"},{"issue":"(3)","key":"2025042208273077300_dgae484-B48","doi-asserted-by":"crossref","first-page":"e861","DOI":"10.1210\/clinem\/dgae173","article-title":"Cardiovascular safety of romosozumab vs PTH analogues for osteoporosis treatment: a propensity-score-matched cohort study","volume":"110","author":"Stokar","year":"2025","journal-title":"J Clin Endocrinol Metab"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgae484\/58650194\/dgae484.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/5\/e1640\/58650194\/dgae484.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/5\/e1640\/58650194\/dgae484.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T08:27:58Z","timestamp":1745310478000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/110\/5\/e1640\/7714517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,16]]},"references-count":48,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,7,16]]},"published-print":{"date-parts":[[2025,4,22]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgae484","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2024,7,16]]}}}